Head-To-Head Review: Biocorrx (OTCMKTS:BICX) vs. Cencora (NYSE:COR)

Biocorrx (OTCMKTS:BICX) and Cencora (NYSE:COR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation.

Valuation and Earnings

This table compares Biocorrx and Cencora”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biocorrx	$800,000.00	10.99	-$3.44 million	($0.19)	-1.61
Cencora	$321.33 billion	0.20	$1.55 billion	$8.32	39.37

Cencora has higher revenue and earnings than Biocorrx. Biocorrx is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biocorrx and Cencora’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biocorrx	N/A	N/A	-59.39%
Cencora	0.50%	176.54%	4.25%

Risk and Volatility

Biocorrx has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, Cencora has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Institutional & Insider Ownership

97.5% of Cencora shares are held by institutional investors. 21.4% of Biocorrx shares are held by insiders. Comparatively, 0.4% of Cencora shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Biocorrx and Cencora, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biocorrx	0	1	0	0	2.00
Cencora	0	2	12	0	2.86

Cencora has a consensus target price of $398.17, indicating a potential upside of 21.57%. Given Cencora’s stronger consensus rating and higher possible upside, analysts clearly believe Cencora is more favorable than Biocorrx.

Summary

Cencora beats Biocorrx on 12 of the 14 factors compared between the two stocks.

About Biocorrx

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

About Cencora

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.